Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

NCT06661915 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06661915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06661915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
August 14, 2025
Completion date
December 31, 2027
Enrollment
78 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase myeloproliferative neoplasm, blast phase myeloproliferative neoplasm, essential thrombocythemia, myelodysplastic/myeloproliferative neoplasm, myeloproliferative neoplasm, not otherwise specified, polycythemia vera, primary myelofibrosis, secondary myelofibrosis